Ocular Therapeutix (OCUL) Revenue (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Revenue of $13.5 million for Q2 2026, little changed year-over-year from $13.5 million in Q2 2025, and up 24.94% on a QoQ basis from $10.8 million in Q1 2026.
Ocular Therapeutix (OCUL) Revenue (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Revenue for 13 years, with the latest figure at $13.5 million in Q2 2026.
- Revenue for Q2 2026 came in at $13.5 million, changed 0.12% year-over-year; the trailing twelve-month figure through Jun 2026 was $52.1 million (down 8.14% YoY), and the FY2025 annual result was $52.0 million, down 18.47% from the prior year.
- Revenue climbed to $13.5 million in Q2 2026, from $10.8 million in the prior quarter.
- Over five years, Revenue peaked at $17.1 million in Q4 2024 and troughed at $10.7 million in Q1 2025.
- A 5-year average of $13.9 million and a median of $13.8 million in 2022 frame the typical range for Revenue.
- The widest annual swing landed in 2022, when Revenue surged 79.61%; it then decreased 27.59% in 2025.
- A 5-year view of Revenue shows it stood at $14.1 million in 2022, then climbed by 5.16% to $14.8 million in 2023, then climbed by 15.41% to $17.1 million in 2024, then slipped by 22.43% to $13.2 million in 2025, then grew by 1.7% to $13.5 million in 2026.
- Per Business Quant data, the three most recent Revenue figures were $13.5 million in Q2 2026, $10.8 million in Q1 2026, and $13.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 13.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.48 Mn |
| Mar 31, 2026 | 10.79 Mn |
| Dec 31, 2025 | 13.25 Mn |
| Sep 30, 2025 | 14.54 Mn |
| Jun 30, 2025 | 13.46 Mn |
| Mar 31, 2025 | 10.70 Mn |
| Dec 31, 2024 | 17.08 Mn |
| Sep 30, 2024 | 15.43 Mn |
| Jun 30, 2024 | 16.44 Mn |
| Mar 31, 2024 | 14.77 Mn |
| Dec 31, 2023 | 14.80 Mn |
| Sep 30, 2023 | 15.08 Mn |
| Jun 30, 2023 | 15.19 Mn |
| Mar 31, 2023 | 13.37 Mn |
| Dec 31, 2022 | 14.08 Mn |
| Sep 30, 2022 | 11.97 Mn |
| Jun 30, 2022 | 12.27 Mn |
| Mar 31, 2022 | 13.19 Mn |
| Dec 31, 2021 | 12.31 Mn |
| Sep 30, 2021 | 12.15 Mn |